Senolytic drugs dasatinib plus quercetin reduced pro-inflammatory cells in small open-label IPF pilot study.
Open-label pilot study in patients with idiopathic pulmonary fibrosis examining intermittent oral dosing of dasatinib plus quercetin over 3 weeks. The intervention aimed to reduce pro-inflammatory cells and cellular senescence markers. The study assessed safety, tolerability, and effects on inflammatory biomarkers, with hypothesized preservation of functional outcomes.
What this changes
The finding has not established an approved change to our evidence assessment.
Source date: May 12, 2020 · Discovered: Sep 16, 2026 · Assessed: — · Research update
What it does not prove
- Limitations have not yet been verified. Read the primary source.
Extracted from supplied source material; model confidence is not a measured probability of correctness.
Study details
- Design
- Rct
- Sample size
- —
- Duration
- —
- Population
- Patients with idiopathic pulmonary fibrosis (IPF)
- Primary outcome
- Safety and tolerability of Dasatinib + Quercetin combination; reduced abundance of pro-inflammatory cells within subjects over baseline
- Effect size
- —
- Significance
- Not reported
- Journal
- Wake Forest University Health Sciences
- Published
- May 12, 2020
Sources
Primary source
- Wake Forest University Health Sciences ↗Clinical trial
Assessment history
Discussion (0)
One thread per scientific event, no matter how many outlets covered it.
No comments yet
Be the first to weigh in on this evidence.